TransCode Therapeutics
RNAZ5.4508.09% ( -0.480 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: TransCode Therapeutics(RNAZ) the EBIT is -7.329 M (-131.1%);the EPS is -21.28 (+69.67%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.01B131.11%
----
----
EPS
-21.27769.67%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf